These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26848174)

  • 1. Quantitative and Simplified Analysis of 11C-Erlotinib Studies.
    Yaqub M; Bahce I; Voorhoeve C; Schuit RC; Windhorst AD; Hoekstra OS; Boellaard R; Hendrikse NH; Smit EF; Lammertsma AA
    J Nucl Med; 2016 Jun; 57(6):861-6. PubMed ID: 26848174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.
    Bahce I; Yaqub M; Errami H; Schuit RC; Schober P; Thunnissen E; Windhorst AD; Lammertsma AA; Smit EF; Hendrikse NH
    EJNMMI Res; 2016 Dec; 6(1):10. PubMed ID: 26857779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
    Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
    J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
    Bahce I; Smit EF; Lubberink M; van der Veldt AA; Yaqub M; Windhorst AD; Schuit RC; Thunnissen E; Heideman DA; Postmus PE; Lammertsma AA; Hendrikse NH
    Clin Cancer Res; 2013 Jan; 19(1):183-93. PubMed ID: 23136193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplified Methods for Quantification of
    Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.
    Verwer EE; van Velden FH; Bahce I; Yaqub M; Schuit RC; Windhorst AD; Raijmakers P; Lammertsma AA; Smit EF; Boellaard R
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1523-31. PubMed ID: 23740374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer.
    Verwer EE; Oprea-Lager DE; van den Eertwegh AJ; van Moorselaar RJ; Windhorst AD; Schwarte LA; Hendrikse NH; Schuit RC; Hoekstra OS; Lammertsma AA; Boellaard R
    J Nucl Med; 2015 Mar; 56(3):365-71. PubMed ID: 25678491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of PD-L1 Expression with
    Huisman MC; Niemeijer AN; Windhorst AD; Schuit RC; Leung D; Hayes W; Poot A; Bahce I; Radonic T; Oprea-Lager DE; Hoekstra OS; Thunnissen E; Hendrikse NH; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2020 Oct; 61(10):1455-1460. PubMed ID: 32060213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Simplified Methods for Quantification of
    Kramer GM; Yaqub M; Vargas HA; Schuit RC; Windhorst AD; van den Eertwegh AJM; van der Veldt AAM; Bergman AM; Burnazi EM; Lewis JS; Chua S; Staton KD; Beattie BJ; Humm JL; Davis ID; Weickhardt AJ; Scott AM; Morris MJ; Hoekstra OS; Lammertsma AA
    J Nucl Med; 2019 Sep; 60(9):1221-1227. PubMed ID: 30850488
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic modeling of a novel hypoxia PET tracer [
    Verwer EE; Zegers CM; van Elmpt W; Wierts R; Windhorst AD; Mottaghy FM; Lambin P; Boellaard R
    EJNMMI Phys; 2016 Dec; 3(1):30. PubMed ID: 27957730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
    Suleiman AA; Frechen S; Scheffler M; Zander T; Kahraman D; Kobe C; Wolf J; Nogova L; Fuhr U
    J Thorac Oncol; 2015 Jan; 10(1):84-92. PubMed ID: 25226426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of quantitative modeling methods in whole-body, dynamic [
    Petrulli JR; Zheng M; Huang Y; Nabulsi NB; Goldberg SB; Contessa JN; Morris ED
    Am J Nucl Med Mol Imaging; 2021; 11(2):143-153. PubMed ID: 34079641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of [
    van de Stadt EA; Yaqub M; Lammertsma AA; Poot AJ; Schober PR; Schuit RC; Smit EF; Bahce I; Hendrikse NH
    EJNMMI Res; 2020 Aug; 10(1):97. PubMed ID: 32804306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
    Bengtsson T; Hicks RJ; Peterson A; Port RE
    J Nucl Med; 2012 Apr; 53(4):530-7. PubMed ID: 22414632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
    J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of 11C-Laniquidar Kinetics in the Brain.
    Froklage FE; Boellaard R; Bakker E; Hendrikse NH; Reijneveld JC; Schuit RC; Windhorst AD; Schober P; van Berckel BN; Lammertsma AA; Postnov A
    J Nucl Med; 2015 Nov; 56(11):1730-5. PubMed ID: 26294297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.